An oral vaccine reduced infection risk in a trial where people were deliberately exposed to high doses of norovirus, and ...

Vaxart Inc., in collaboration with researchers from multiple academic institutions, evaluated the VXA-G1.1-NN vaccine against ...

Vaxart's oral norovirus vaccine shows promise in mid-stage trials, reducing infections by 30%. Read more here.

Vaxart Inc (VXRT) reports significant revenue growth and clinical advancements, despite facing operational hurdles and NASDAQ ...

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced its business update and financial results for the first quarter of ...

In April 2025, Vaxart completed enrollment of all 60 participants for its Phase 1, open label, dose ranging clinical trial evaluating its second-generation oral norovirus vaccine constructs head ...

Covid vaccine manufacturer Moderna has completed a new site in the UK, which it says will help prepare the the country ...